Sonia Zúñiga

Since mid-October, northern China has reported an increase in influenza-like illness compared to the same period in the previous three years. On 21 November, the media and the ProMED system reported outbreaks of pneumonia of undiagnosed cause in children in northern China. According to the World Health Organization (WHO), it is unclear whether these are related to the overall increase in respiratory infections previously reported by the Chinese authorities or are separate episodes. In a statement, the WHO has officially requested detailed information from China on this increase in respiratory illnesses and outbreaks of childhood pneumonia.

Several media outlets are reporting cases of "camel flu" or MERS-CoV at the World Cup in Qatar, including three French national team players. However, no cases have been confirmed and the news reports speak of non-specific symptoms that could be due to any other infectious condition. This coronavirus, discovered in 2012, has a high case fatality rate and before the start of the competition, the WHO had already asked fans travelling to the country to watch out for possible symptoms.

During Pfizer's appearance before the European Parliament this week, a company executive responded to the question of whether "Pfizer's vaccine was tested to stop transmission of the virus (SARS-CoV-2) before going to market" by saying "no".

To estimate the effectiveness of two or three doses of vaccines against covid-19 infection and hospitalisation, researchers in Denmark conducted a study of all previously uninfected Danish residents aged 12 years and older. The conclusion of the research, which is published in PLOS Medicine, is that a third dose provided greater protection against infection and hospitalisation with omicron than two vaccines.

The Minister of Health, Carolina Darias, announced in an interview on La Sexta that there will be a fourth dose of the covid-19 vaccine "for the entire population".

Two studies published in The Lancet Infectious Diseases confirm that covid-19 vaccines offer additional protection for those already infected with SARS-CoV-2, especially against severe disease.

La EMA ha recomendado hoy la autorización de la quinta vacuna frente a la covid-19 para mayores de 18 años: la estadounidense Novavax, la primera basada en una plataforma de proteínas recombinantes.